Skip to main content

University of Utah Licenses Omicia's Opal for Genomic Interpretation

Premium

Omicia and the University of Utah said this week that they have signed a two-year licensing agreement that allows researchers involved in the Utah Genome Project use Opal, Omicia's platform for analyzing genomics in research and clinical applications, to analyze disease causing variants.

The Utah Genome Project is a large-scale, genome sequencing and analysis initiative that aims to discover new disease-causing genes and develop more personalized testing and treatment procedures. Under the terms of the agreement, researchers and clinicians involved in the project will be able to use Opal on a cost-per-genome basis to identify variants that are associated with autoimmune and metabolic disorders and other ailments.

The financial details of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.